ESR1 and breast cancer: Nevertheless, it cannot be excluded that the low levels of FoxO3a observed in ER+ BC patients might be, at least for the subgroup receiving tamoxifen therapy, a consequence of the gradual acquisition of a tamoxifen resistant phenotype.